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Tumor heterogeneity presents a challenge for infer-
ring clonal evolution and driver gene identification.
Here, we describe a method for analyzing the
cancer genome at a single-cell nucleotide level. To
perform our analyses, we first devised and validated
a high-throughput whole-genome single-cell se-
quencing method using two lymphoblastoid cell
line single cells. We then carried out whole-exome
single-cell sequencing of 90 cells from a JAK2-
negative myeloproliferative neoplasm patient. The
sequencing data from 58 cells passed our quality
control criteria, and these data indicated that this
neoplasm represented a monoclonal evolution. We
further identified essential thrombocythemia (ET)-
related candidate mutations such as SESN2 and
NTRK1, which may be involved in neoplasm pro-
gression. This pilot study allowed the initial charac-
terization of the disease-related genetic architecture
at the single-cell nucleotide level. Further, we estab-
lished a single-cell sequencing method that opens
the way for detailed analyses of a variety of tumor
types, including those with high genetic complex
between patients.INTRODUCTION
Tumor evolution is an important area in cancer research because
information on fundamental genetic changes that occur as
a tumor develops is essential for effective diagnosis, prognosis,
and therapy (Cairns, 1975; Nowell, 1976). However, character-
izing the underpinnings of this process remains difficult. Current
theories propose that neoplasms arise either from monoclonal
or polyclonal somatic mutant cells, and there is evidence that
supports both a gradual change and an instantaneous change
in the genome to promote progression (Stephens et al., 2011;
Visvader, 2011). The heterogeneous nature of tumors, however,
makes it difficult for researchers to analyze the intratumoral
genetic structure and identify key changes during neoplasm
progression. Without additional cell sorting experiments, hema-
topoietic tumors, in particular, are very heterogeneous, making it
especially difficult to identify genetic mutations that have amajor
impact on cancer development.
Myeloproliferative neoplasms are hematopoietic tumors. They
originate from genetic variations occurring in hematopoietic
stem cells or progenitors, which lead to abnormal differentiation
and myelopoiesis. A typical myeloproliferative neoplasm is
essential thrombocythemia (ET). ET is characterized by malig-
nant myeloid and a sustained proliferation of megakaryocytes,
which leads to an increasing number of circulating platelets,
typically in excess of 600 3 109/l. ET affects about 2 out of
100,000 adults per year, with the incidence rate increasing inCell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc. 873
recent years (Mesa et al., 1999). ET is also a slowly progressing
neoplasm, with 50% of patients being asymptomatic and the
remainder presenting vasomotor, thrombotic, or hemorrhagic
disturbances (Tefferi, 2001).
Previous studies on ET have provided evidence supporting
both a monoclonal and a polyclonal origin for ET initiation and
proliferation (Tefferi, 2010). Approximately 55% of ET patients
harbor JAK2 mutations. However, JAK2 and other rare muta-
tions identified can be found in both ET and other types of myelo-
proliferative neoplasms. Thus, none of these mutations provide
unique markers to infer the evolution history of ET, nor could
they be traced back to a common originating clone (Tefferi,
2010). One approach to revealing the underlying genetic mech-
anisms of ET is to assess mutations within the individual cancer
cells, which would circumvent issues of tumor heterogeneity.
Recent work on breast cancer has demonstrated the potential
applicability of single-nucleus sequencing technology for
characterizing tumor evolution (Navin et al., 2011). Specifically,
Navin et al. (2011) investigated copy number variation (CNV) in
single tumor cells using DOPWGA followed by DNA sequencing
to determine cell population structure and tumor evolution
patterns in a single breast tumor. This study provided an impor-
tant breakthrough for research of tumor evolution and offered
a way to assess the genetic details of tumor structure. This
method, however, is not suitable for assessing the genetic char-
acteristics of single tumor cells at a single-nucleotide resolution,
and, at this stage, it cannot provide high genome coverage;
thus, this approach does not allow the detection of the single-
nucleotide changes that commonly underlie tumor development.
The use of MDA for WGA analysis, however, allows greater
resolution and genome coverage due to the MDA products
being a higher molecular weight DNA (average length > 10 kb),
which results in significantly higher genome recovery (Dean
et al., 2002b). Thus, this technique, as we demonstrate here,
can allow for whole-genome sequencing, with high accuracy at
the nucleotide level.
Here, we present a high-throughput single-cell sequencing
method to analyze tumor evolution in cancers. We use this tech-
nique to perform single-cell genetic analysis of a JAK2-negative
ET patient. We design and test our single-cell sequencing
method using two single cells from a lymphoblastoid cell line
and evaluated its whole-genome recovery, amplification unifor-
mity, sensitivity, and specificity. We then perform whole-exome
sequencing of 90 single cells from a typical JAK2-negative ET
patient and obtain a comprehensive genetic landscape of ET.
Analysis of the somatic mutant allele frequency spectrum
(SMAFS) reveals that this ET neoplasm was likely of monoclonal
origin, and statistical analyses of the genes carrying mutations
provide a list of candidate genes that might be involved in
neoplasm progression.
RESULTS
Whole-Genome Single-Cell Sequencing of Cells Derived
from a Previously Sequenced Individual
To develop and test a method for carrying out whole-genome
single-cell sequencing at a single-nucleotide level, we used cells
that were derived from an individual whose genome had been874 Cell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc.previously sequenced. This genome would serve as a whole-
tissue genome sequence control to assess our method. We
therefore constructed a lymphoblastoid cell line from lympho-
blast cells previously obtained at BGI from the individual (YH)
who provided DNA for the first Asian diploid genome sequence
(Wang et al., 2008). Under an inverted microscope and through
cascade dilution, we randomly extracted two single cells (here-
after referred to as YH-1 and YH-2) from the YH lymphoblastoid
cell line using standard manipulation methods (Spits et al., 2006)
(Figure S1A available online). We then carried out whole-genome
amplification (WGA) based on multiple displacement amplifica-
tion (MDA), which uses theV29 enzyme to amplify DNA in a linear
process (Dean et al., 2002a), on the DNA from each single cell.
The amplicon showed a peak size at 23 kb, which is much
longer than the degenerate oligonucleotide-primed (DOP; ran-
domly amplify the whole genome with degenerated PCR primer)
PCR (<1 kb) from the same samples (Figures S1B and S1C)
and from others reports (Navin et al., 2011). We used DNA
fluorometry-based quantitation to select products that were
quantitation qualified (see Experimental Procedures). These
were assayed for genomic integrity using ten housekeeping
gene PCR tests for each single cell. The products that passed
this filter underwent massively parallel whole-genome single-
cell sequencing using paired-end 100-bp reads and 350 bp
size inserts. We uniquely mapped and aligned 42.27 Gb (YH-1)
and 47.65 Gb (YH-2) of high-quality sequences to the human
reference genome (Hg18) with the SOAP program (Li et al.,
2009b) and obtained 97.25% of bases with 15.88 3 mean fold
coverage of the whole genome of YH-1 and 95.64% of bases
with 17.90 3 mean fold coverage of the whole genome of
YH-2 (Table 1). We also carried out massively parallel whole-
genome sequencing on a multicell sample from the YH lym-
phoblastoid cell line as a control and obtained 99.91% of bases
with 18 3 mean fold coverage of the whole genome (com-
parable with the single-cell data) (Table 1). For each sample,
using only the reads that could be uniquely mapped to the refer-
ence genome, we identified single-nucleotide polymorphisms
(SNPs) with SOAPsnp (Li et al., 2009b).
For standard genome sequencing in which researchers are
trying to identify mutations involved in disease, 303 is the typical
sequencing depth. However, here we are using the sequencing
data of two identical YH cells to assess the fidelity of our ampli-
ficationmethod (i.e., allele dropout (ADO) and the false discovery
rate), not to identify mutations. Thus, a mean sequencing depth
of 153–183 is sufficient, given that the sequence for these cells
is already known.
Single-Cell Sequencing Data Are of High Sensitivity
and Have a Distinct Genome Distribution from Tissue
Sequencing
To evaluate the whole-genome recovery, amplification unifor-
mity, and accuracy of single-cell sequencing, we used a Circos
map (Krzywinski et al., 2009) to graphically assess the whole-
genome coverage and characteristics of our single-cell
sequencing data by looking at the sequence recovery and
distribution uniformity on the whole genome (Figure 1). The
sequence from both single cells covered more than 90% of the
human reference genome (Figures 1C and 1D), and additional
Table 1. Single-Cell Sequencing Data Generation and Evaluation
Samples
Whole Genome Coding Region Data Evaluation
mean
depth
% of bases
atR 1 depth
mean
depth
% of bases
atR 1 depth
% of bases
atR 15 depth
% of bases
atR 18 depth
FD#/# ADO #/#
YH-1 15.88 97.25 18.95 94.05 18.09 13.96 2/99,152
(2.02 3 105)
18,807/246,314 (7.64%)
YH-2 17.9 95.64 19.13 91.74 35.43 29.50 3/99,152
(3.03 3 105)
36,523/246,314 (14.8%)
Control 18.04 99.91 20.53 97.30 62.80 47.20 – –
(FD #/#) False discovery site number/high-confidence homozygous control subsets number. High-confidence homozygous control subsets were
defined as sites that are consistent between control (subset with quality score of 99) and the first Asian diploid genome study (Illumina 1M genotyping
and Illumina sequencing). (ADO #/#) ADO site number/high-confidence heterozygous control subsets number. High-confidence heterozygous control
subsets were defined as the sites that are consistent in the first Asian diploid genome study between Illumina 1M genotyping and Illumina sequencing.analysis showed that single-cell sequencing retrieved > 95% of
the bases in the reference genome at a 153 sequencing depth
(Figure S1D), which indicated high genome coverage sensitivity.
The cumulative distribution of the sequencing fold coverage
across the coding regions showed that 25% of the bases
were covered by 183 or more in the single-cell sequencing
data, which is 50% less than that of the multicell (unamplified)
control (red and blue in Figure S1E). The lower coverage was
expected, as there was likely bias in the amplification process.
We also looked at the distribution of the sequence data across
the genome to determine whether there were genomic regions
that had a specific impact on the WGA process. The data distri-
bution exhibited a correlation with the GC content distribution
in some regions of the genomes (Figures 1B–1D). Accordingly,
we examined how the single-cell sequencing reads were dis-
tributed across the genome relative to the GC content, and the
distribution pattern of the reads showed that the GC content
effected the even distribution of amplification products from
single-cell WGA, with regions of extreme GC content showing
lower amplification efficiency (Figure S1F). The median GC
content in places with 0 coverage (i.e., amplification failure) in
gene-coding sequence regions and the whole genome was
60.12% and 49.40%, respectively. These percentages were
higher (p value < 0.001, Student’s t test) than the average 41%
GC content of human reference genome (Figure S1G). Similar
assessments of read distribution coverage in repeat regions
or at different chromosomal locations, however, showed no
significant correlation (Figures S1H–S1I). These data indicated
that amplification efficiency was primarily dependent on GC
content.
Allele Dropout and FalseDiscovery Affect the Sensitivity
of Single-Cell Sequencing
To detect the specificity and fidelity of the genomic sequence
from the single cells, we first evaluated the allele dropout
(ADO), which shows whether nonamplification occurred in one
of the alleles present in a heterozygous sample, as loss of hetero-
zygous sites would lead to calling false negatives in the single-
cell sequencing data. We calculated the false negative ratio
per sequencing depth using the multicell sample sequence as
a control and determined the ADO per cell as the median of
false negative ratios (Figure S2A). The average ADO ratio for all
single cells was 11% (Table 1), which is comparable to that ofprevious analyses (Spits et al., 2006), indicating that the single-
cell sequences are of standard quality. As an additional means
to determine the specificity and fidelity of single-cell sequencing,
we evaluated the false discovery rate in the single-cell se-
quencing data. The false discovery ratio is defined as a false
discovery (FD) heterozygous site in a homozygous sample,
which might arise due to amplification, hybridization, or
sequencing errors. Taking the multicell sample sequence as
control, we found that only twothree bases in the single-cell
sequencing were discrepant within a subset of 99,152 high-
confidence homozygous background sites, indicating that our
single-cell sequencing had an extremely low error rate. The
average false discovery ratio of our single-cell sequencing was
2.523 105 (Table 1), which was similar to that of the multicell
sample sequencing using the same sequencing platform,
according to a previous report (Bentley et al., 2008). As YH
was a male, we further assessed our data quality by determining
the false heterozygous allele rate across the X chromosome
between each single cell and the multicell sample sequencing
data (Figure S2B). We also examined the sequencing data of
the mitochondrial DNA from the two YH single cells and found
no false discovery site, further indicating the low amplification
error of our methodology.
Allele Dropout and False Discovery Show No Bias
Relative to Genomic Region or Base Type
To assess the impact of ADO and false discovery artifacts in our
sequence, we analyzed the distribution of these artifacts relative
to genomic region and base type. We analyzed the distribution
across chromosome 1, and, with the exception of regions near
the telomeres and centromere, there was an even distribution
of the ADO and false discovery bases (Figure 2A), indicating
that the artifacts occurred randomly. Additionally, we built
a high-resolution map of the artifact distribution to assess
whether there was a prevalence of common artifacts between
two single cells (Figure 2A) and found very few that were in
common. These analyses also provided a method by which
to detect true nucleotide changes from amplification and
sequencing artifacts when mutations are present in a substantial
number of individual cells.
We next evaluated the per base characteristics of these
artifacts. We determined whether the ADOs were random with
regard to different bases by calculating the number of ADO forCell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc. 875
Figure 1. Graphic Representation of the Whole Genome of Two Single YH Cells
(A) Karyotype of the human reference genome (Hg18).
(B) GC content distribution of the reference genome (height of orange rectangles ranges from 0%–70%, bin = 1Mb). (C) Whole-genome coverage of YH-2 (height
of blue rectangles ranges from 03–403, bin = 1 Mb).
(D) Whole-genome coverage of YH-1 (height of blue rectangles ranges from 03–403, bin = 1 Mb).
(E) Gene density across the reference genome (Hg18) (gradually changing green represents from 0 to 30 genes per 100 kb).
See also Figure S1.each of the four base types of YH-1 and YH-2 in heterozygous
SNPs of the multicell sequence data (Figure 2B). We observed
no significant difference (Fisher’s exact test, p = 0.3) between
the ADO numbers for the four base types. We also evaluated
the ‘‘mutation change’’ base distribution spectrum of the false876 Cell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc.discovery sites. Unlike the ADO, the false discovery bases
showed a preference for C:G to T:A changes (Fisher’s exact
test, p < 0.01) (Figure 2C). This same pattern has been observed
previously in other tumor sequencing data (Greenman et al.,
2007) and is also fit with the expectation that transitions occur
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Figure 2. Characteristics of Artifacts in the Two YH Cells Induced by Single-Cell Sequencing
(A) Distribution of ADO and false discovery bases across chromosome 1.
(B) Evaluation of ADO on the four different base types.
(C) Evaluation of false discovery on different types of base changes.
(D) The fraction of genes that failed to amplify in all captured genes.
(E) Relative distribution of amplification failure ratio of biological categories of genes.
See also Figure S2.
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Table 2. Whole-Exome Sequencing Data Production of the ET
Mixed Multicell Sample and the Oral Mucosal Epithelium Mixed
Multicell Sample
Sample
Mean Fold
Coverage
Fraction of
Targets
Covered by
at Least 13
Fraction of
Targets
Covered by
at Least 20 3
Tissue
sequencing
LN-T1 57.62 0.97 0.58
LC-T1 91.12 0.99 0.88
Whole exome that we captured was 36,184,808 bp. LN-T1 is the oral
mucosal epithelium mixed multicell sample, and LC-T1 is the ET mixed
multicell sample.more readily than transversions during cell division. These data
indicated that the presence of artifacts will have very limited
artifactual impact on the mutation pattern that we would see in
our ET by single-cell sequencing. Additionally, our analyses
here allowed us a means to detect and remove artifacts that
do occur and thus improve the quality of our mutation calling
quality, and this was incorporated into our SNP calling method
described below in our ET single-cell sequencing.
WGA Errors Do Not Selectively Affect Genes with
Specific Biological Functions
We further assessed whether the genomic regions that were not
sufficiently covered in our single-cell sequencing data were likely
to influence our biological analysis. Here, we selected genes
from areas in which amplification failed and identified 640 genes
in which a total of 643 amplification failure exons (Figure 2D).
Gene ontology (GO) mapping analysis showed that there was
no enrichment with regard to any specific biological function
for any of these genes (Figures 2E and S2C). The correlation
coefficient (R2) of each proportion of biological process category
between amplification failure genes and all captured genes
was 0.99 (Figure S2D), showing that these data were highly
consistent and had no systematic bias in gene amplification
failure. Thus, it is unlikely that WGA led to selective loss of genes
involved in specific biological pathways, and thus it would have
limited influence in subsequent biological analyses. Taking
together all of the above error bias analyses, these results
indicated that our single-cell sequencing strategy is of high
sensitivity and specificity and can be used to carry out accurate
genetic analyses.
Single-Cell Exome Sequencing of a JAK2-Negative
ET Patient
Having established the single-cell sequencing technology as
a qualified means to explore genetic changes at a single-cell
nucleotide level, we used this method to investigate intercellular
genomic heterogeneity and tumor evolution in ET. We applied
our single-cell sequencing method to individual cells from a
previously healthy 58-year-old Chinese male ET patient without
a family history of leukemia. This patient is a typical JAK2V617F
wild-type (validated by PCR-Sanger sequencing) ET patient
with more than 80% abnormal myeloid cells within his bone
marrow (Figure S3A), from whom we could infer neoplasm
evolution and could potentially also obtain novel genetic infor-878 Cell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc.mation on this type of cancer in this individual (see Extended
Experimental Procedures for detailed clinical report).
Using sufficient dispersion and cascade dilution of cells, we
randomly selected 82 cells from a sampling of fresh bone
marrow and 8 cells from a sampling of normal oral mucosal
epithelium by micromanipulation, as described above. We
sequenced matched tissue samples from fresh bone marrow
and normal oral mucosal epithelium. Here, to provide a more
cost-effective means of analysis and because our interest was
to look at genes involved in cancer development, we used a
standard exome sequencing strategy instead of whole-genome
sequencing to assess genetic variation within the coding regions
of the single cells.
In the ET single-cell study, on average, we sequenced the
37 Mb targeted exome regions of each cell (90 cells total) to a
mean depth of 303 (Table S1). We evaluated the whole-exome
single-cell sequencing and defined the genetic characteristics
of ET using the bioinformatics analysis pipeline shown in Fig-
ure S3B. We filtered out the cells that had coverage < 70%, as
the information from these is more likely to be negatively influ-
enced by amplification/capture errors. The cells from the mature
oral mucosal epithelium all had average target base coverage
< 70%; thus, the 58 cells that we used for further analysis were
all from the bone marrow (Table S1). In all, we obtained 58 single
cells, with an average of70%of target bases atR 5 depth. This
coverage is sufficient for confident population variant calling
when multiple cells carry the same variant (Table S1) (Li et al.,
2010; Yi et al., 2010). For instance, if five of the cells contain
the same variant at a specific site, then having a 5-fold coverage
for each cell is the equivalent of calling the variant of this site
at 25-fold coverage, and this coverage is sufficient to call
mutational variants when mathematical models (e.g., Bayesian
estimation, maximum likelihood estimation) is incorporated into
the analysis (Li et al., 2010; Yi et al., 2010).
For the corresponding tissue sequencing control, we se-
quenced the 37 Mb targeted exome regions of ET-mixed
multicell sample (more than 1 3 106 cells) to a mean depth of
91.123 and the oral mucosal epithelium mixed multicell sample
(more than 1 3 106 cells) to a mean depth of 57.623 (Table 2).
Thus, we obtained more than 88% of target bases atR 203 of
the ET mixed multicell sample.
Population Somatic Mutation Calling and Validation
of This Patient
To carry out a tumor cell population variant analysis, we needed
to detect SNPs within all of our samples from which to create an
overall genotype spectrum for the tumor tissue. We first used the
unique reads from each sample to detect SNPs in the exome
regions using SOAPsnp and assembled a consensus sequence
for each individual cell and the two tissue samples. We then
grouped these to define a cell population genotype, as is used
in population genetic analysis (Behar et al., 2010; Yi et al., 2010).
To determine the accuracy of the whole-exome single-cell
sequencing, we determined the ADO and false discovery ratio
as described previously (see also Table S2). The average ADO
of single-cell sequencing of ET was determined by the ADO of
the 58 ET cells in the heterozygous SNPs in both tissue
sequencing of the normal and ET samples using dbSNP as the
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Figure 3. Schematic of the Somatic Muta-
tion Calling Method in the Single-Cell
Population and the Somatic Mutant Allele
Frequency Correlation between Single-Cell
Data and the Tissue of ET
(A) A normal pair of chromosomes is shownwith an
A/G SNP and two homozygous sites. Following
WGA, PCR, and sequencing, a genotype is
assembled from the reads. In the vicinity of the
SNP, the region surrounding the A allele failed to
amplify, and the result is an allele dropout (ADO)
identifiable by a homozygous call in a single normal
cell and a heterozygous call in the normal bulk
tissue. The ‘‘A’’ in red represents a false discovery
mutation in the normal single cell. The false
discovery ratio can be estimated from these sites
in normal single cells as compared to the normal
bulk DNA.
(B) The same region of the tumor pair of chromo-
somes is shown with a putative somatic mutation
detected in the genome of bulk tumor DNA as well
as the genome of single tumor cell.
(C) Shown are ten hypothetical single tumor cells
with putative somatic mutations. A mutation found
in only a single cell is more likely to be a false
discovery and is removed from consideration.
Assuming a false discovery rate (p) = 105, the
probability of finding the samemutation in a third or
fourth single cell is extremely low and also signifi-
cantly lower than mutation, as depicted in the
graph.
(D) Correlation between single-cell sequencing
and tissue sequencing. The somatic mutant allele
frequency in ET single-cell sequencing is indicated
as an unfolded (that is, each genotype is taken
as two alleles for a diploid-genome cell) site
frequency of mutant alleles. The somatic mutant
allele frequency in ET tissue sequencing is
indicated as a read frequency of mutant alleles.
R2 here refers to the square of the correlation
coefficient.
See also Figure S3 and Tables S1, S2, and S3.background control. We obtained an average ADO of 43.09%.
The false discovery ratio was 6.043105, which was determined
using eight oral mucosal cells compared to 4,923,547 homozy-
gous sites in oral mucosal tissue sequencing. The higher ADO
and false discovery ratio observed here, as compared to those
we obtained from the whole-genome sequencing of YH-1 and
YH-2, may be due to differences in cell status and cell pattern
and to loss of heterozygosity during the exome capture step.
To detect high-confidence point somatic mutations and
circumvent the influence of amplification artifacts among the
single-cell population, we defined a true mutation only if it
occurred in a specified number of cancer cells (Figures 3A–
3C). We carried out an extremely rigorous binomial test based
on false discovery ratio, qualified ET cell number, and whole-
exome length size to eliminate false somatic mutations that
might have been caused by random single-cell sequencing
errors. We also required that the somatic mutant loci be presentin at least five ET cells and be homozygous normal in the oral
mucosal epithelium tissue sequence data. We identified a total
of 712 point somatic mutations in the exomes and flanking
regions (within 100 bp) (Tables S3 and S4). We further assessed
the coverage of each identified mutation, and 100% of the
mutant alleles were covered by 103 or more reads, which is
sufficient for our mutation calling by binomial test and also
more rigorous than previous exome sequencing (R83) (Li
et al., 2009a). Analysis of the base mutation type revealed that
the majority of mutations were base substitutions between C:G
and T:A (Figure S4A) in both the single-cell sequencing and
tissue sequences, which is concordant with that seen in other
cancers (Greenman et al., 2007).
We validated the somatic mutations from the single-cell
sequencing in two ways. First, we compared all of the single-
cell sequencing somatic mutations to those identified in the ET
tissue sequencing. The correlation coefficient (R2) of the somaticCell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc. 879
mutation allele frequency between single-cell sequencing and
tissue sequencing was 0.75, which indicated a highly consistent
frequency (Figure 3D). Second, we validated the identified
somatic mutations by randomly selecting 30 somatic mutations
and assessed their presence in 52 randomly selected cells using
PCR-Sanger sequencing; 90% (27 out of 30) were present in the
PCR data.
The Use of 58 ET Cells Is Suitable for Identifying
the Main Clonal Makeup of the ET Sample
Before carrying out additional genetic analyses on the identified
mutations, we first determinedwhether 58 cells were sufficient to
provide sufficient information on the genetic changes that
occurred during ET development. The most important prerequi-
site of our evaluation is that we had randomly selected single
cells from the bone marrow sample of the ET patient. To assess
this, we examined the number of somatic mutations observed
using an increasing number of cells. As expected, the number
of somatic mutations increases with the use of data from greater
cell numbers, but the number of somatic mutations reaches
a plateau of cumulative somatic mutations at 25 single cells
(Figure S4B). Statistic analysis showed that sequencing more
cells would almost not increase the number of somaticmutations
called from the cell population (cell number from 25 to 58, kappa
square test, p = 0.57). This indicated that we have covered the
majority of the somatic mutations within the ET sample; thus,
this sample size is sufficient for identifying the main clonal
architecture of this neoplasm.
Although it is possible that we might observe clones that were
more highly selected, our single-cell exome sequencing data
is comparable with the tissue exome data with regard to the
capability of detecting different frequencies of mutations from
different clones. Additionally, given that the sensitivity of exome
capture in tissue sequencing is about 95%, the tissue sequence
data might contain 5% of the heterozygous sites that are lost
(Figure S4C). However, for single-cell sequencing, the likelihood
of the same sites being lost in different cells by chance is
extremely low. These results were also consistent with the
observations of sequencing errors in multicell sequencing and
of the ADO and amplification artifacts in single-cell sequencing
(Figures S4D–S4F).
Population Analysis Indicated that None of the
Sequenced ET Cells Were Normal Cells
Given the potential that normal cells could have been collected
bychanceduringour isolation of ETcells,wedeterminedwhether
there were some normal bone marrow cells among the 58 cells
from the neoplasm. We performed a principle component
analysis (PCA) (Jolliffe, 2002) based on the somatic mutations
(Figure 4A) and found that the first component (eigenvector 1)
showed that the ET cells were clearly different from the oral
epithelium (tissue sequencing), indicating that no obviously
normal cells were mixed with the ET cells. We also observed
that, on each eigenvector, the ET cells were also separated
from each other, indicating that the ET cells have substantial
genetic diversity. However, we did not detect any significant
subclusters among the ET cells on each eigenvector, indicating
that the ET cells may be of monoclonal origin (discussed below).880 Cell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc.The JAK2-Negative ET Patient Harbors a Distinct Set
of Mutations
To confirm that this ET patient did not carry mutations in genes
previously reported in ET studies and that this form of ET was
truly JAK2 negative, we first tested whether any of our identified
somatic mutations were present in reported ET-mutated genes:
TET2, MPL, ASXL1, CBL, IDH, and IKZF1. All of these genes
were appropriately covered by our sequencing reads, but none
hadmutations (mutant reads inmore than two of the single cells).
Further screening of the reads mapping across JAK2 exon 12
and exon 14, MPL exon 10 in tissue sequencing data of ET,
and in the control data indicated that the previously reported
hot spots were not altered in our ET patient.
Copy number alterations are rare in essential thrombocythe-
mia (Kawamata et al., 2008; Stegelmann et al., 2010). We per-
formed loss-of-heterozygous (LOH) analysis across the whole
exome by comparing the heterozygous rate between the paired
tissue sequencing data. There were no obvious LOH changes
around these hot spots across the genome (Fisher’s exact test,
p > 0.05; Figure S4G). These data all confirmed that this patient
was truly JAK2 negative and further demonstrated that an eluci-
dation of the genetic underpinnings of this type of ET required
further genetic analyses to identify mutations that are important
for cancer development in this patient.
The Population Genetic Pattern Indicates Monoclonal
Origin of ET Cells
Our PCA analysis provided the first indication that this ET likely
was of monoclonal origin. To make full use of our single-cell
sequencing data to reconstruct the intratumoral genomic archi-
tecture and infer the possible developmental pattern, we exam-
ined the somatic mutant allele frequency spectrum (SMAFS)
of our ET cells. It is important to note that, if the sequence cover-
age was insufficient to determine the genotype with certainty for
each individual cell, the population genetic inferences based
on called (inferred) somatic mutations would potentially lead
to serious biases and possibly false inferences. We therefore
used a Bayesian estimation-based method to call the site
frequency spectrum to calculate the somatic allele frequency at
each site for all ET cells (Yi et al., 2010). Given the randomness
of ADO for each base type, the SMAFS is likely to be an unbiased
site frequency spectrum. No significant selection signal was
observed (Figure 4B), as there were no more nonsynonymous
SNPs than synonymous SNPs at the lowest or highest somatic
mutant allele frequencies. The SMAFS also showed an apparent
increase in the number of sites at the50%somaticmutant allele
frequency, both for synonymous and nonsynonymous somatic
mutations. This indicates that all of the single cells contain
specific heterozygous somatic mutant alleles or that half of the
single cells contain homozygous somatic mutant alleles (but
this is extremely unlikely). Thus, this patient’s ETmost likely orig-
inated from one clone or expanded from a single clone that had
gained sufficient growth advantage after neoplasm expansion
during progression to become the primary initiating clone.
However, this does not rule out the possibility that cells of other
clonal origin are present in an extremely low number.
To provide further genetic evidence of the proposed mono-
clonal origin, we calculated the likelihood of these ET cells
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Figure 4. Genetic Characteristics of the ET Patient
(A) Principle component analysis (PCA) of the mutations in the ET cells (red) and thematched normal tissue (green). (B) Somatic mutant allele frequency spectrum
(SMAFS) of ET. The SMAFS of ET was calculated for each mutation site of the ET by taking the oral mucosal epithelium mix as a control. The mutations are
indicated as synonymous (green), nonsynonymous (purple), and noncoding (blue) mutations.
(C) Monoclonal and polyclonal evolution simulation of ET. The SMAFS of simulated one (orange), two (yellow), three (purple), four (green), and five (blue) clonal
evolutions was calculated and compared with the SMAFS of ET (red) in the coding regions.
See also Figure S4 and Table S4.having monoclonal evolution by carrying out an in silico clonal
modeling simulation. For the simulation, we used a modified
mathematical model with fit parameters from several previous
reports (Abramson and Melton, 2000; Haeno et al., 2009; Lynch
and Conery, 2003; Yachida et al., 2010) (see Extended Experi-
mental Procedures for details). To simplify the evolution model,
we only calculated the SMAFS of clones originating and
proliferating from 1, 2, 3, 4, and 5 clones by the average of
100 times simulation. We started our simulation with the muta-
tions obtained during each cell cycle across the human whole-
exome region, which was comparable with our observations
for single-ET cell sequencing. When comparing these simulated
models with that observed in our ET patient, we found that
the single-clone simulation (monoclonal evolution) was most
similar to the SMAFS distribution that we obtained (Figure 4C).
Taken together, these data indicated that a monoclonal evolu-tion pattern of this neoplasm was most likely. This pattern might
also be observed under conditions in which there was a brief
polyclonal origin of the neoplasm but in which a specific clone
subsequently had a very strong growth advantage over all
other mutated clones; this would also produce a monoclonal
evolution pattern and would provide the same genetic char-
acteristics of monoclonal evolution.
Mutated Genes and Their Potential Roles
in ET Monoclonal Progression
To identify key genes underlying ET monoclonal initiation and
progression, we carried out a series of analyses as outlined
in Figure S3C. Here, we assessed the 171 somatic mutations
out of the total 712 somatic mutations (Table S4A) that were
present in the coding regions that have a higher likelihood of
having a functional impact. Of these coding somatic mutations,Cell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc. 881
Table 3. Key Genes and Their Known Biological Functions in ET Neoplasm Progression
Gene Name Mutation Type Amino Acid Changes Functional Data
SESN2 Missense P87S SESN2 encoded a member of the sestrin family of SESN1-related proteins
and was an antioxidant activated by p53. Mutation in SESN2 may lead to DNA
damage and genetic instability.
ST13 Nonsense Q349* ST13 encodes an Hsc70-interacting protein that controls the activity of regulatory
proteins such as steroid receptors and regulators of proliferation or apoptosis.
A mutation in ST13 may contribute to loss of apoptotic control and may lead
to abnormal proliferation.
NTRK1 Missense N323S A known oncogene; a mutation in NTRK1 may contribute to sustained angiogenesis
and cell proliferation.
ABCB5 Missense G365V Upregulation of ABCB5 has been shown to be responsible for multidrug resistance
in several cancers.
FRG1 Missense C205Y May be involved in pre-mRNA splicing.
ASNS Missense D118V Is an asparagine synthetase.
TOP1MT Missense S479L Acts as a DNA topoisomerase important during mitochondrial DNA synthesis.
DNAJC17 Missense A292P Is a DnaJ homolog subfamily C member 1778 were nonsynonymous and present in a total of 71 genes
(Table S4B).
We determined which of these 71 genes were likely to contain
protein-damagingmutations or had been identified previously as
associated with cancer. Using SIFT (Kumar et al., 2009), we
found that 15 genes were likely to contain protein-damaging
mutations (including protein truncation). We also found that three
additional genes of the 71 (MLL3, NTRK1, and PDE4DIP) were
present in the COSMIC Cancer Gene Census database (Futreal
et al., 2004).
We further assessed the relative likelihood of these 18 genes
being important to ET development using a modified Poisson
model, whereby we proposed that driver genes were likely to
contain significantly more nonsynonymous mutations than
background mutations (Youn and Simon, 2011). Such driver
gene prediction methods have previously been used in anal-
yses of a variety of tumor types (Carter et al., 2009; Youn
and Simon, 2011) and have been based on the mutation
frequency in different samples from different patients. Of our
18 candidate genes, we identified 8 genes that had a signifi-
cantly higher prevalence of protein-function-alternative somatic
mutations, with a Q score R 1.0 (%10% false discovery rate)
(Table 3). Thus, these genes would have the highest likelihood
of being involved in ET initiation and/or progression. Of interest,
among these eight genes, four (SESN2, ST13, DNAJC17, and
TOP1MT) had Q scores that were significantly higher than all
other candidate genes (Figure 5). We propose that these
genes may be of interest for future biological investigation in
relation to ET.
DISCUSSION
Here, we developed a robust MDA-based single-cell sequenc-
ing method by carrying out whole-genome single-cell se-
quencing of two lymphoblastoid cell line cells. The data
analysis indicated that it provides a higher sensitivity (more
than 95% of bases with 18 3 mean fold coverage of a whole
genome of a single cell) than does DOP-PCR-based single-cell882 Cell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc.sequencing and a comparable specificity (false discovery
rate: 2.52 3 1056.04 3 105) with other amplification-based
methods.
We next applied this single-cell sequencing method to a
typical myeloproliferative neoplasm, ET. Based on the popula-
tion genetic analyses of 58 qualified single cell exomes, we
used somatic allele frequency data to demonstrate that this ET
was likely of monoclonal origin and identified several genes
that may play roles in ET neoplasm initiation and progression.
These analyses demonstrate the ability of the method to begin
characterizing the genetic architecture of the neoplasm, its
clonal evolution, and candidate driver genes.
In particular, as SESN2 is known to be involved in DNA
damage and genetic instability (Sablina et al., 2005), change
in SESN2 function could lead to more rapid accumulation of
additional somatic mutations. In addition, our identification of
a mutation in the NTRK1 gene is especially intriguing, given
that it is a tyrosine kinase receptor that functions in a similar
biological pathway as JAK2, the gene that has been found to
be the most commonly mutated gene in ET. Because this patient
was JAK2mutation negative, it raises the possibility that interfer-
ence of this type of biological process through a variety of
genetic mutations may be important for ET progression. Other
genes like the tumor suppressor ST13 (Yi et al., 2010) and the
oncogene ABCB5 (Frank and Frank, 2009) may also be involved
in ET progression in concert with ASNS, DNAJC17, TOP1MT,
and FRG1, which may be of interest for future biological investi-
gation as well.
Overall, in addition to shedding light on ET development, our
study demonstrates that single-cell sequencing enables the
detection of numerous point mutations and that whole-exome
sequencing of single tumor cells provides an excellent tool for
assessing the complexity of small genetic changes in a variety
of tumors tumor at a greater resolution (Xu et al., 2012, this issue
of Cell). Accompanying single-cell sequencing with SMAFS and
matched clone-evolution simulation analyses also enables
researchers to define whether a tumor arises from a single or
polyclone evolution process. Our method further opens the
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Figure 5. Key Gene Identification of the ET Patient
The driver gene prediction analysis of the 18 ET candidate genes is indicated
as Q score. The vertical axis is the Q score, and the circle size (diameter)
indicates the cell mutation frequency.way for carrying out studies on a variety of complex diseases and
biological processes that would benefit from the advantages of
single-nucleotide resolution from individuals cells. This would
be especially useful for diseases that develop additional and
multiple mutations over time, which alter disease progression
and would therefore impact treatment strategies.
EXPERIMENTAL PROCEDURES
Sample Collection
YH lymphoblastoid cell line, which was constructed from the healthy individual
who provided DNA for the first Asian genome sequence (http://yh.genomics.
org.cn/), was obtained from BGI. For ET patient, fresh bone marrow cells
and normal oral mucous epithelium were obtained from a 58-year-old Chinese
JAK2 V617F-wild-type ET male patient. The platelet count was 600 3 109/l,
whereas the white cell count and the hemoglobin level were normal. Informed
written consent was obtained from the study participant. The studies were
conducted in accordancewith the Declaration of Helsinki II andwere approved
by the local Ethical Committees.
Collection, Lysis, and WGA of Single Cells
Every step during the experiment was reduced to strict minimum. With
sufficient dispersion and cascade dilution of cells, single cells were randomly
isolated from bloods or digested (collagenase I and IV) tissues into PCR-ready
tubes using an inverted microscope and a mouth-controlled, fine hand-drawn
microcapillary pipetting system made in house. The single-cell isolation was
visually confirmed by microscopy and documented as micrographs. The
cells were washed three times using the elution buffer. WGA of single cells
was performed with REPLI-g Mini Kit (QIAGEN, Inc.) according to the instruc-
tions of the manufacturer, along with a no cell reaction as a negative control
and a reaction of human tissue genomic DNA as positive control.
Quantitation and Genome Integrity Assessment of the WGA
Products
The DNA concentration of the WGA products was measured with Quant-iT
assays (Invitrogen Life Science, Inc.) according to the manufacturer’s instruc-
tion. Then, genomic integrity of the qualified products (>60 ng/ml) was assayed
by PCR amplification of ten housekeeping genes representing ten genes
interspersed across ten different chromosomes. WGA products of best per-
formance in relation to housekeeping PCR (R8/10) and Qubit (>60 ng/ml)
were selected for downstream experiments. Every step was performed along
with a sample of human tissue genomic DNA as positive and a no template
reaction as negative control, respectively.
Sequencing of Two Lymphoblastoid Cell Line Cells
For single cells from YH lymphoblastoid cell line, 2 mg genomic DNA from the
selected WGA products was used to construct 350 bp sequencing libraries
and then subjected to massively parallel sequencing using the HiSeq2000(Illumina, Inc.), with the paired-end 100 bp read option, according to themanu-
facturer’s instructions.
Whole-Exome Capture and Sequencing of Samples from the ET
Patient
For matched tissues from the ET patient, high molecular weight genomic DNA
was extracted from freshly frozen bone marrow cells and normal oral mucous
epithelium. For each DNA sample (both single cells and matched tissues) from
the ET patient, whole-exome capture was accomplished based on liquid
phase hybridization of 2 mg sonicated genomic DNA to the bait cRNA library
that was synthesized on magnetic beads using SureSelect Human All Exon
kit (Agilent Technology, Inc.), according to the manufacturer’s protocol. The
captured targets were subjected to massively parallel sequencing using
HiSeq2000 with the paired-end 100 bp read option, according to the manu-
facturer’s instructions.
Public Data Set Access
Human (Homo sapiens) reference genome sequence (Hg18) and its annotation
files (dbSNP v128) were downloaded from University of California Santa Cruz
Genome Bioinformatics (http://genome.ucsc.edu/). The YH reference genome
and the YHSNPs files were downloaded from the First Asian Diploid Genome
database (http://yh.genomics.org.cn/). The target region files of exome
capture were downloaded from the Agilent website (http://www.genomics.
agilent.com).
Reference Guide Genome Assembly and SNP Calling
SOAPaligner/SOAP2 version 2.20 was used to align all sequencing reads to
the Hg18 reference genome with a maximum of two mismatches and nongap
parameters. For YH single cells and matched tissue, all reads mapping
uniquely to the whole genomewere selected for SNP calling; for the ET patient,
all reads mapping uniquely to exome regions and 100 bp flanking regions were
selected for SNP calling. SOAPsnp version 1.03 was used for calculating the
likelihoods of genotypes for each cell and matched tissue (see Extended
Experimental Procedures).
Data Evaluation by ADO and False Discovery Ratio
With the final SNPs, the ADO was defined as the random nonamplification of
one of the alleles present in a heterozygous sample. The false discovery ratio
was defined as a false heterozygous site in a homozygous sample. The eval-
uation of ADO and false discovery ratio were performed comparing the
single-cell data and the tissue sequencing control data (see Extended Exper-
imental Procedures).
Randomness Evaluation of ADO and False Discovery Ratio
We evaluated randomness of ADO by calculating the counts of ADO of the four
base types in YH-1 and YH-2 among the previously noted high-confidence
heterozygous SNPs. We evaluated the randomness of false discovery ratio
by separating the artifacts into six different mutation types. The numbers of
different base types of ADO were normalized. We used Fisher’ exact test to
calculate the p value of the variation between base types.
High-Confidence Somatic Mutation Identification and Experiment
Verification
To eliminate random errors induced by single-cell sequencing, we created
abinomial test todetect high-confidencepoint somaticmutations. Theputative
somatic mutations were filtered by the following criteria: (1) the oral mucosal
epithelium tissue sequence was normal homozygous for the site, and (2) the
mutation was present in at least five ET cells among the total 58 qualified ET
cells, with criterion (2) set using a binomial test with false discovery ratio, qual-
ified ET cell number, and whole-exome length size to eliminate random errors.
PðiÞ=Cinpið1 pÞðniÞ
PðiÞ$S<1
wherein i is the cell number of mutants of a specific mutation, n is the qualified
ET cell number, p is the false discovery ratio, P(i) is the probability underCell 148, 873–885, March 2, 2012 ª2012 Elsevier Inc. 883
binomial distribution, and S is the whole-exome length size after which
criterion (2) was set according to the minimum cell number that fulfilled the
above equation. High-confidence somatic mutations in ET cells were then
randomly selected for PCR-Sanger experiment verification.
Principal Component Analysis
To identify the most variable factors in classifying subgroups among single
cancer cells, we utilized an R package, pcaMethods v1.12.0 (http://rss.acs.
unt.edu/Rdoc/library/pcaMethods/), in performing the PCA based on the
genotyping result at all somatic mutation sites on each single cell. Missing
values were automatically estimated by probabilistic method within the
R package.
Correlation of Somatic Mutant Allele Frequency between
Single-Cell Sequencing and Tissue Sequencing
Correlation coefficient of determination is a goodness-of-fit measure for
models based on the proportion of explained variance. The somatic mutant
allele frequency in ET single-cell sequencing was indicated as the unfolded
(that is, each genotype is taken as two alleles for a diploid-genome cell) site
frequency of mutant alleles, and the somatic mutant allele frequency in ET
tissue sequencing was indicated as read frequency of mutant alleles.
Somatic Mutant Allele Frequency Spectrum Analysis
To take uncertainty in genotype calling and allele frequency estimation into
account, instead of utilizing a Bayesian estimation-based method called
site frequency spectrum (SFS) on population individuals (Yi et al., 2010), we
used this SFS to calculate the somatic mutant allele frequency in each
SM site of all single cells, based on the same methods of estimating allele
frequencies from reads in one site and additional estimating of sample allele
frequencies.
In Silico Clonal Modeling Simulation
In our simulation, we used a modified mathematical model with fit parameters
from several previous reports (Abramson andMelton, 2000; Haeno et al., 2009;
Lynch and Conery, 2003; Yachida et al., 2010) (see Extended Experimental
Procedures). Using fit parameters, we calculated the SMAFS of monoclonal
evolution and polyclonal evolution (originating and proliferating from 2, 3, 4,
and 5 clones) by the average of 100 times simulation, respectively.
Driver Gene Predication
We used amodified Poissonmodel that hypothesized that driver genes lean to
contain significantly more nonsynonymous mutations than the background
mutations (Youn and Simon, 2011) (see Extended Experimental Procedures).
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